TScan Therapeutics
TScan Therapeutics is a fully integrated clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
TScan Therapeutics is a fully integrated clinical-stage biotechnology company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for patients with cancer. Founded in early 2018, it began as a discovery-driven company using a novel target discovery platform and has since moved into clinical-stage development. Its current focus is on in vivo engineering of TCR-Ts to treat solid tumors, with lead candidates targeting PRAME and MAGE-A4. The company is headquartered in Waltham, United States.
History
TScan Therapeutics was founded in early 2018 to discover and develop TCR-T therapies using a novel target discovery platform. The company began as a discovery-driven organization and progressed through platform development, clinical candidate advancement, and clinical-stage development. Its stated focus has evolved toward in vivo engineering of TCR-Ts for solid tumors, and it has identified two lead candidates, one targeting PRAME and the other targeting MAGE-A4, to advance into IND-enabling studies.
Products and positioning
Striving to become a leader in developing in vivo-engineered TCR-T therapy for the treatment of solid tumor indications.
TSC-101
Evaluated in Phase 3 ALLOHA-2™ pivotal trial in patients with heme malignancies
Recent events
TScan Therapeutics appoints Brian M. Silver to its board[5]
Reported:
TScan Therapeutics announced Brian M. Silver's appointment to its board of directors.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/tscan-therapeutics-united-states · Editorial policy · How profiles are compiled